Success Metrics

Clinical Success Rate
74.2%

Based on 23 completed trials

Completion Rate
74%(23/31)
Active Trials
5(10%)
Results Posted
78%(18 trials)
Terminated
8(17%)

Phase Distribution

Ph phase_2
16
33%
Ph early_phase_1
1
2%
Ph phase_1
23
48%
Ph not_applicable
1
2%
Ph phase_3
5
10%

Phase Distribution

24

Early Stage

16

Mid Stage

5

Late Stage

Phase Distribution46 total trials
Early Phase 1First-in-human
1(2.2%)
Phase 1Safety & dosage
23(50.0%)
Phase 2Efficacy & side effects
16(34.8%)
Phase 3Large-scale testing
5(10.9%)
N/ANon-phased studies
1(2.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.5%

23 of 38 finished

Non-Completion Rate

39.5%

15 ended early

Currently Active

5

trials recruiting

Total Trials

48

all time

Status Distribution
Active(7)
Completed(23)
Terminated(15)
Other(3)

Detailed Status

Completed23
Terminated8
Withdrawn7
Recruiting3
unknown2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
48
Active
5
Success Rate
74.2%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (2.2%)
Phase 123 (50.0%)
Phase 216 (34.8%)
Phase 35 (10.9%)
N/A1 (2.2%)

Trials by Status

enrolling_by_invitation12%
not_yet_recruiting12%
withdrawn715%
terminated817%
unknown24%
recruiting36%
active_not_recruiting24%
completed2348%
suspended12%

Recent Activity

Clinical Trials (48)

Showing 20 of 48 trialsScroll for more
NCT01306019Phase 1

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

Recruiting
NCT04177004Phase 1

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Suspended
NCT06325709Phase 1

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Recruiting
NCT06959771Phase 1

Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study

Recruiting
NCT06851767Phase 1

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

Enrolling By Invitation
NCT01746849Phase 2

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Active Not Recruiting
NCT02356159Phase 1

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Completed
NCT05139004Phase 1

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Active Not Recruiting
NCT06986382Phase 1

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

Not Yet Recruiting
NCT01085617

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed
NCT01746173Phase 2

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Terminated
NCT00376935Phase 2

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

Completed
NCT00881556Early Phase 1

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Terminated
NCT01237951Phase 2

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Completed
NCT01200329Phase 2

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Completed
NCT02589145Phase 1

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Terminated
NCT03315078Phase 1

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Unknown
NCT01712945Phase 1

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis

Terminated
NCT03531281Phase 1

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Withdrawn
NCT00728585Phase 2

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
48